Lanean...
Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low‐ and High‐Mineral‐Content Water on the Tablet in Healthy Adults
Dolutegravir (DTG) is approved in the United States to treat HIV‐1‐infected patients weighing ≥30 kg. A dispersible DTG tablet formulation was recently developed for pediatric patients. This study compares the pharmacokinetics (PK) of the dispersible tablet with that of a previously evaluated granul...
Gorde:
| Argitaratua izan da: | Clin Pharmacol Drug Dev |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley and Sons Inc.
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5697680/ https://ncbi.nlm.nih.gov/pubmed/28168828 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.332 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|